Filter Results:
(660)
Show Results For
- All HBS Web
(660)
- People (2)
- News (224)
- Research (298)
- Events (4)
- Multimedia (12)
- Faculty Publications (181)
Show Results For
- All HBS Web
(660)
- People (2)
- News (224)
- Research (298)
- Events (4)
- Multimedia (12)
- Faculty Publications (181)
Page 1 of 660
Results →
- Web
Kraft Accelerator
The Harvard Business School Kraft Precision Medicine Accelerator convenes best-in-class
leaders from the business, medical, scientific, and technological communities to identify
and solve challenges slowing the advancement of precision medicine,... View Details
- June 2020
- Case
Breakthroughs at Blueprint Medicines
By: Richard G. Hamermesh, Kathy Giusti and Susie L. Ma
Precision medicine company Blueprint Medicines was building a successful track record for bringing drug therapies to market 40% faster than average. The company had spent $40 million dollars and two years building a compound library that became its drug development... View Details
Keywords: Precision Medicine; Cancer; Biotechnology; Drug Development; Strategy; Expansion; Science; Genetics; Information Technology; Entrepreneurship; Organizational Culture; Management; Growth and Development; Pharmaceutical Industry; United States; Cambridge; Massachusetts
Hamermesh, Richard G., Kathy Giusti, and Susie L. Ma. "Breakthroughs at Blueprint Medicines." Harvard Business School Case 820-001, June 2020.
- 2019
- Chapter
Characterizing the Drug Development Pipeline for Precision Medicines
By: Amitabh Chandra, Craig Garthwaite and Ariel Dora Stern
BOOK ABSTRACT: Personalized and precision medicine (PPM)—the targeting of therapies according to an individual’s genetic, environmental, or lifestyle characteristics—is becoming an increasingly important approach in health care treatment and prevention. The advancement... View Details
Chandra, Amitabh, Craig Garthwaite, and Ariel Dora Stern. "Characterizing the Drug Development Pipeline for Precision Medicines." Chap. 5 in Economic Dimensions of Personalized and Precision Medicine, edited by Ernest R. Berndt, Dana P. Goldman, and John W. Rowe, 115–158. University of Chicago Press, 2019.
- September 2017 (Revised February 2023)
- Case
Intermountain Healthcare: Pursuing Precision Medicine
By: Richard G. Hamermesh, Kathy E. Giusti, Robert S. Huckman and Julia Kelley
Headquartered in Salt Lake City, Intermountain Healthcare operates 23 hospitals and hundreds of clinics in Utah and Idaho and provides insurance to approximately 850,000 patients through its insurance arm, SelectHealth. In 2013, Intermountain, known for its commitment... View Details
Keywords: Precision Medicine; Healthcare; Innovation; Cancer; Cancer Research; Health Care; Technology; Health Care and Treatment; Innovation Leadership; Disruptive Innovation; Entrepreneurship; Decision Choices and Conditions; Health Industry; Insurance Industry; Utah; United States; North America
Hamermesh, Richard G., Kathy E. Giusti, Robert S. Huckman, and Julia Kelley. "Intermountain Healthcare: Pursuing Precision Medicine." Harvard Business School Case 818-018, September 2017. (Revised February 2023.)
- Article
Ushering in Safe, Effective, Secure, and Ethical Medicine in the Digital Era
By: William J. Gordon, Andrea Coravos and Ariel Dora Stern
From clinical trials to care delivery, advanced, digitally enabled technologies and analytics offer new approaches to how we think about medicine, health, and biology. The COVID-19 pandemic has accelerated this conversation, and forced a roadmap, once measured in years... View Details
Gordon, William J., Andrea Coravos, and Ariel Dora Stern. "Ushering in Safe, Effective, Secure, and Ethical Medicine in the Digital Era." npj Digital Medicine 4, no. 56 (2021).
- 01 May 2019
- News
Getting Personal With Precision Medicine
- July 2001 (Revised August 2005)
- Case
Medicines Company, The
It is early 2001 and the Medicines Co. just received FDA approval to market Angiomax, a blood thinner to be used during angioplasties and heart procedures. It is intended to be a better alternative to Heparin, an 80-year-old drug that costs less then $10 per dose. The... View Details
Keywords: Business Model; Change Management; Decision Choices and Conditions; Cost Management; Price; Product Marketing; Product Launch; Product Development; Risk and Uncertainty; Health Industry; Pharmaceutical Industry
Gourville, John T. "Medicines Company, The." Harvard Business School Case 502-006, July 2001. (Revised August 2005.)
- 17 Aug 2020
- News
Democratizing Medicine
Inspired by a family member’s experience with a lack of timely access to health care, Carlos Reines (MBA 2014) built RubiconMD make sure others get the medical expertise they need, when they need it. In this interview, he talks about how his company helps increase and... View Details
- 01 Dec 2013
- News
Your Own Medicine
WILLIAMS CHARLEY SECKLER in the midst of the first-ever trial for a DMD treatment at Johns Hopkins University. Photo courtesy the Seckler Family by Dan Morrell There's this picture of Charley Seckler from last summer that his mom has sent to everyone: Her 12-year-old... View Details
- March 17, 2017
- Article
How Economics Can Shape Precision Medicines
By: Ariel Dora Stern, Brian M. Alexander and Amitabh Chandra
Many public and private efforts in coming years will focus on research in precision medicine, developing biomarkers to indicate which patients are likely to benefit from a certain treatment so that others can be spared the cost—financial and physical—of being treated... View Details
Stern, Ariel Dora, Brian M. Alexander, and Amitabh Chandra. "How Economics Can Shape Precision Medicines." Science 355, no. 6330 (March 17, 2017): 1131–1133.
- April 1986 (Revised May 1993)
- Case
Computers in Medicine
Herzlinger, Regina E. "Computers in Medicine." Harvard Business School Case 186-282, April 1986. (Revised May 1993.)
- 24 Apr 2014
- News
Medicine made personal
Australia-born Arjun Goyal (MBA 2014) credits HBS with helping him focus his career on life sciences, specifically “personalized medicine”—a tailored approach to treatment based on analysis of patient populations. With his classmate Louis Levy (MBA 2014), whom he met... View Details
- 15 Mar 2019
- News
Targeting cancer and careers: Precision Medicine
- 17 Oct 2018
- Video
Unlocking the Potential of Precision Medicine
- August 2, 2005
- Article
Medicine for Medicaid
By: R. E. Herzlinger
Herzlinger, R. E. "Medicine for Medicaid." Wall Street Journal (August 2, 2005), A10.
- 16 Oct 2015
- HBS Seminar
Katrine Bosley, Editas Medicine
- Article
Time-Driven Activity-Based Costing in Emergency Medicine
By: Robert S. Kaplan, Brian J. Yun, Anand M. Prabhakar, Jonathan Warsh, John Brennan, Kyle E. Dempsey and Ali S. Raja
Value in emergency medicine is determined by both patient-important outcomes and the costs associated with achieving them. However, measuring true costs is challenging. Without an understanding of costs, emergency department (ED) leaders will be unable to determine... View Details
Keywords: Time-Driven Activity-Based Costing; Emergency Room; Health Care and Treatment; Value; Cost Management; Activity Based Costing and Management
Kaplan, Robert S., Brian J. Yun, Anand M. Prabhakar, Jonathan Warsh, John Brennan, Kyle E. Dempsey, and Ali S. Raja. "Time-Driven Activity-Based Costing in Emergency Medicine." Annals of Emergency Medicine 67, no. 6 (June 2016): 765–772.
- May 2023 (Revised June 2023)
- Supplement
Novartis (B): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Care and Treatment; Business Model; Production; Business Strategy; Pharmaceutical Industry
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (B): Reimagining Medicine." Harvard Business School Supplement 723-444, May 2023. (Revised June 2023.)
- May 2023 (Revised June 2023)
- Case
Novartis (A): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Care and Treatment; Business Model; Leadership; Pharmaceutical Industry; Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (A): Reimagining Medicine." Harvard Business School Case 723-443, May 2023. (Revised June 2023.)